Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fonds de Solidarité Ftq
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | May 30, 2024
Finance
Venture Report: Canadian VC Amplitude closes new fund; CinRx’s series C
Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy
BioCentury | May 17, 2023
Regulation
May 17 Quick Takes: Intercept falls on negative tone of FDA briefing docs
Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Apr 27, 2022
Deals
April 26 Quick Takes: CD24 will be new focus of Forty Seven founders as Stanford spinout Pheast debuts
Plus Nkarta follows breakthrough data with $200M raise, and updates from Epitopea, Forcefield and
BioCentury | Mar 8, 2022
Emerging Company Profile
Congruence: identifying protein folding correctors
Montreal-based newco is cataloging properties of misfolded proteins and building a virtual chemical library to screen for stabilizers
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
BioCentury | Feb 10, 2022
Finance
Patience is priceless: crossovers deliver $140M series C to Versant-backed Ventus
Funding gives Ventus firepower to take three programs to IND
BioCentury | Aug 11, 2021
Finance
Aug. 10 Quick Takes: SPAC to deliver GreenLight to NASDAQ with $282M
Eliem prices $80M IPO, plus updates from Moderna, Arcturus, Liminal, Sydnexis and LQT
BioCentury | Jul 26, 2021
Finance
Seeking deals from all areas of U.S. and Canada, Lumira raises $220M fourth fund
About 80% will go to therapeutics, the remainder to medtech
Items per page:
1 - 10 of 65